Antidrug Antibodies and Drug Development: Challenges in the Immunotherapy Era.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33692029.
- Also identified by DOI 10.1158/1078-0432.CCR-21-0168.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Novel antibody formats such as bispecifics have increased risk of immunogenicity, impacting safety and efficacy. LY3415244, a novel T-cell immunoglobulin and mucin-domain-containing molecule-3 (TIM3)-PDL1 (programmed death (ligand) 1) bispecific caused neutralizing antibody-drug antibodies (ADA) in 12 of 12 patients and required study termination. Novel approaches are needed to ameliorate and manage this undesirable effect of therapeutic antibodies.<i>See related article by Hellmann et al., p. 2773</i>.
Medical subject headings
- Antibodies, Bispecific
- Pharmaceutical Preparations